Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $1.13
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Apr 13, 26 |
Daily · Wilder smoothing
| HC Wainwright & Co. |
| maintain |
| Buy |
| Buy |
| Nov 24, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Aug 18, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| May 20, 25 | Maxim Group | upgrade | Hold | Buy |
| Apr 2, 25 | Scotiabank | maintain | Sector Perform | Sector Perform |
| Nov 15, 24 | Ladenburg Thalmann | downgrade | Buy | Neutral |
| May 16, 24 | BTIG | maintain | Buy | Buy |
| Mar 7, 24 | Scotiabank | maintain | Sector Outperform | Sector Outperform |
| Nov 13, 23 | Maxim Group | downgrade | Buy | Hold |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 28.89 | Oscillator | Buy |
| Stochastic %K (14, 3, 3) | 6.76 | Oscillator | Buy |
| Williams %R (14) | -92.50 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.07 (Hist -0.04) | Oscillator | Strong Sell |
| Average Directional Index (14) | 25.17 (+DI 15.9 / -DI 29.7) | Trend | Strong Sell |
| EMA 20 | 1.34 | MA | Strong Sell |
| SMA 20 | 1.40 | MA | Strong Sell |
| EMA 50 | 1.36 | MA | Strong Sell |
| SMA 50 | 1.38 | MA | Strong Sell |
| SMA 200 | 1.25 | MA | Strong Sell |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 4, 26 | Luderer Albert | director, officer: Interim Chief Executive | P-Purchase | 4,000 @ $1.21 | $4.84K |
| Aug 21, 26 | Luderer Albert | director, officer: Interim Chief Executive | P-Purchase | 4,000 @ $1.22 | $4.86K |
| Aug 3, 26 | Adamchak Mark | officer: Principal Accounting Officer | A-Award | 5,000 @ $1.12 | $5.60K |
| Aug 3, 26 | Dixon Jonathan V. | officer: General Counsel | A-Award | 15,000 @ $1.12 | $16.80K |
| Aug 3, 26 | Oldakowski Mark | officer: Chief Operating Officer | A-Award | 15,000 @ $1.12 | $16.80K |
| Aug 3, 26 | Hastie Alex Reid | officer: Chief Scientific Officer | A-Award | 54,000 @ $1.12 | $60.48K |
| Aug 3, 26 | Oldakowski Mark | officer: Chief Operating Officer | 15,000 @ $1.12 | $16.80K | |
| Aug 3, 26 | Adamchak Mark | officer: Principal Accounting Officer | 5,000 @ $1.12 | $5.60K |
TTM vs. 5-year historical average (annual ratios)
| Metric | BNGO | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.3x | -3.1x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -0.5x | EPS est. -2.14 | Elevated |
| Price / Book | 0.4x | 1.1x | Discount |
| Price / Sales | 0.4x | 12.8x | Discount |
| EV / EBITDA | -0.7x | -3.3x | Discount |
| Return on equity | -78.8% | — | Weak |
| Gross margin | 47.5% | 18.5% | Above hist. |
| Debt / Equity | 0.21 | 0.37 | Conservative |
| Piotroski / Altman Z | 4/9 | Z -22.33 | Distress |
Discounted cash flow model
Stock news · updated daily
SAN DIEGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed test (LDTs), today announced expansion of optical genome mapping (OGM) based testing of hematologic malignancies at Memorial Sloan Kettering Cancer Center (MSK), following approval from the New York State Department of Health (NYSDOH).
FY2025 · 10-K disclosure
Independent research teams at MD Anderson Cancer Center, the University of Oulu, and the Josep Carreras Leukaemia Research Institute report that optical genome mapping (OGM) uncovers clinically significant genomic alterations missed by conventional cytogenetics, with direct implications for risk stratification across MDS, AML, and therapy-related myeloid neoplasms Independent research teams at MD Anderson Cancer Center, the University of Oulu, and the Josep Carreras Leukaemia Research Institute report that optical genome mapping (OGM) uncovers clinically significant genomic alterations missed by conventional cytogenetics, with direct implications for risk stratification across MDS, AML, and therapy-related myeloid neoplasms
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 10, 2026 | -0.67 | -0.64 | Beat 4.5% | $8.17M |
| May 13, 2026 | -0.81 | -0.76 | Beat 6.2% | $6.69M |
| Mar 23, 2026 | -0.81 | -0.03 | Beat 96.3% | $7.95M |
| Nov 13, 2025 | -1.81 | -1.59 | Beat 12.2% | $7.37M |
| Aug 14, 2025 | -2.69 | -1.99 | Beat 26.0% | $6.73M |
| May 14, 2025 | -3.49 | -1.15 | Beat 67.0% | $6.46M |
FY2025 · 10-K disclosure
| SC 13G/A | Aug 14, 2026 | 2026-08-14 14:42:04 | View |
| 10-Q | Aug 10, 2026 | 2026-08-10 16:10:01 | View |
| 8-K | Aug 10, 2026 | 2026-08-10 16:05:14 | View |
| 4 | Aug 5, 2026 | 2026-08-05 17:28:01 | View |
| 4 | Aug 5, 2026 | 2026-08-05 17:27:39 | View |
| 4 | Aug 5, 2026 | 2026-08-05 17:27:13 | View |
Proxy statement (DEF 14A) disclosures